| Literature DB >> 34164126 |
Rubina F Rizvi1, Kelly J Thomas Craig1, Rezzan Hekmat1, Fredy Reyes1, Brett South1, Bedda Rosario1, William J Kassler1, Gretchen P Jackson1,2.
Abstract
OBJECTIVES: Non-pharmaceutical interventions (e.g. quarantine and isolation) are used to mitigate and control viral infectious disease, but their effectiveness has not been well studied. For COVID-19, disease control efforts will rely on non-pharmaceutical interventions until pharmaceutical interventions become widely available, while non-pharmaceutical interventions will be of continued importance thereafter.Entities:
Keywords: COVID-19; Quarantine; incidence; influenza pandemic 1918–1919; mortality; non-pharmaceutical interventions; pandemics; patient isolation; transmission
Year: 2021 PMID: 34164126 PMCID: PMC8188982 DOI: 10.1177/20503121211022973
Source DB: PubMed Journal: SAGE Open Med ISSN: 2050-3121
Summary of study characteristics.
| Reference number | Reference, year | Pathogen | Geography | Study design; | Funding source(s)
| |
|---|---|---|---|---|---|---|
| Location | Continent | |||||
| 1 | Ali et al., 2013
| Influenza A (H1N1 subtype) | India | Asia | Modeling study; | Academia; research council |
| 2 | Andradóttir et al., 2011
| Influenza A (H1N1 subtype) | North America | North America | Modeling study; | Industry |
| 3 | Bolton et al., 2012
| Influenza A (H1N1 subtype) | Mongolia | Asia | Modeling study; | Government |
| 4 | Bootsma et al., 2007
| Influenza A (H1N1 subtype) | The United States | North America | Modeling study; | Government; research council |
| 5 | Caley et al., 2008
| Influenza A (H1N1 subtype) | Australia | Australia | Modeling study; | Government; research council |
| 6 | Cowling et al., 2020
| COVID-19 | Hong Kong | Asia | Observational study; | Government |
| 7 | Davey et al., 2008
| Influenza A (H1N1 subtype) | The United States | North America | Modeling study; | Government |
| 8 | Esquivel-Gómez et al., 2018
| Non-specific | Mexico | North America | Modeling study; | Government; research council |
| 9 | Ferguson et al., 2005
| Influenza A (H5N1 subtype) | Thailand | Asia | Modeling study; | Government |
| 10 | Ferguson et al., 2020
| COVID-19 | The United Kingdom; The United States | Europe; North America | Modeling study; | Academia; government; research council |
| 11 | Fong et al., 2020
| Various influenza strains and subtypes; seasonal and future | Multiple countries | Global | Systematic review; | Academia; government; research council |
| 12 | Glass et al., 2006
| Influenza A (H2N2 subtype) | The United States | North America | Modeling study; | Research council |
| 13 | Halloran et al., 2008
| Future influenza pandemic | The United States | North America | Modeling study; | Government |
| 14 | Hatchett et al., 2007
| Influenza A (H1N1 subtype) | The United States | North America | Case-series; | Government |
| 15 | He et al., 2013
| Influenza A (H1N1 subtype) | The United Kingdom | Europe | Modeling study; | Government |
| 16 | Hellewell et al., 2020
| COVID-19; SARS-coronavirus | Non-specific | NA | Modeling study; | Academia |
| 17 | Hens et al., 2009
| Future influenza pandemic | Europe | Europe | Modeling study; | Government |
| 18 | Herrera-Valdez et al., 2011
| Influenza A (H1N1 subtype) | Mexico | North America | Modeling study; | Academia |
| 19 | Jackson et al., 2014
| Influenza | Non-specific | NA | Systematic review; | Government |
| 20 | Kelso et al., 2009
| Influenza A (H3N2 subtype) | Australia | Australia | Modeling study; | Government; research council |
| 21 | Kelso et al., 2013
| Influenza A (H1N1, H3N2 and H5N1 subtypes) | Australia | Australia | Modeling study; | Academia |
| 22 | Khazeni et al., 2014
| Influenza A (H1N1, H5N1 and H7N9 subtypes) | The United States | North America | Modeling study; | Government |
| 23 | Koo et al., 2020
| COVID-19 | Singapore | Asia | Modeling study; | Government |
| 24 | Maier and Brockmann, 2020
| COVID-19 | Mainland China | Asia | Modeling study; | Academia; industry |
| 25 | Markel et al., 2007
| Influenza A (H1N1 subtype) | The United States | North America | Modeling study; | Government |
| 26 | Prem et al., 2020
| COVID-19 | Mainland China | Asia | Modeling study; | Government; research council |
| 27 | Teslya et al., 2020
| COVID-19 | The Netherlands | Europe | Modeling study; | Government |
| 28 | Zhang et al., 2020
| COVID-19 | Mainland China | Asia | Modeling study; | Government; research council |
NA: not applicable.
Adapted from Oxford Levels of Evidence: Level 2a, systematic review with homogeneity of 2b or better studies; modeling studies were considered similar to economic and decision analysis study types; Level 2b, analysis based on clinically sensible costs or alternatives; limited review(s) of the evidence, or single studies, and including multi-way sensitivity analyses; Level 3b, analysis based on limited alternatives or costs, poor-quality estimates of data, but including sensitivity analyses incorporating clinically sensible variations; Level 4, case-series.
Funding source considerations: academia includes both government and private institutions; government; industry; and research councils include both for-profit and not-for-profit.
Figure 1.Study selection process.
Summary of articles identified by search queries, and tracking of articles that were included and excluded across the study screening phases with reasons for exclusion of full-texts.
Summary of outcome-based evidence from social distancing non-pharmaceutical interventions identified.
| Type of social distancing NPI | Subtype NPI | Number of studies
| Study designs included | Outcome-based evidence for consideration in decision-making related to the effectiveness of social distancing NPIs on disease outcomes
|
|---|---|---|---|---|
|
| Non-specific | 11 | Modeling | INCIDENCE: |
| Mass gathering cancelations/avoiding crowding | 11 | Case-series; modeling; observational | INCIDENCE: | |
| School closure | 20 | Case-series; modeling; observational | INCIDENCE: | |
| Travel restriction | 4 | Modeling; observational | INCIDENCE: | |
|
| Workplace policy | 11 | Case-series; modeling | INCIDENCE: |
|
| Border control | 2 | Modeling | INCIDENCE: |
| Close contacts/household | 11 | Modeling; observational | INCIDENCE: | |
| Onboard | 1 | Modeling | TRANSMISSION: | |
| Voluntary self-protection | 3 | Modeling | INCIDENCE: | |
|
| Zones (city) | 1 | Modeling | TRANSMISSION: |
|
| Cases
| 13 | Modeling; observational | INCIDENCE: |
| Hospitalized patients | 2 | Modeling; observational | MORTALITY: |
COVID-19: coronavirus disease 2019; I: disease infectivity factor; NPIs: non-pharmaceutical interventions; R0: reproduction number.
Details provided in abstraction Supplementary Table III.
Multiple subtypes of social distancing NPIs were used in studies.
Substantial heterogeneity was noted in outcome measures employed to report each outcome, that is, disease incidence (e.g. infection rate or incident rate, incidence proportion or attack rate); disease transmission (e.g. R0, disease infectivity (I) factor), and disease mortality (e.g. case fatality proportion, peak excess death rates, and mortality rates).
General social distancing (i.e. reduced interactions between potentially infectious individuals—but not diagnosed—in a broader community).
Quarantine (i.e. involves the restriction of movement of presumably infectious individuals as they may have been exposed to disease).
Isolation (i.e. separation of diagnosed individuals).
Included suspected and undiagnosed cases.
Figure 2.Study intervention hierarchy for data analysis. This graphic visualizes the study details regarding data collection concerning interventions to mitigate or control viral pandemics or epidemics. Single (non-pharmaceutical interventions (NPIs) or pharmaceutical interventions (PIs)) interventions and/or multiple interventions with combinations of exclusive social distancing NPIs, social distancing NPIs plus other NPIs, social distancing NPIs plus PIs, and/or social distancing NPIs plus other NPIs and PIs.
Superscripts denote the labeling of specific interventions used to categorize study results provided in the data abstraction.
Figure 3.Summary of outcomes by study with respect to basic reproduction number (R0) and quality assessment. The bubble plot lists included studies by year (y-axis) and outcome (x-axis; disease incidence, mortality, and/or disease transmission). The size of the circle represents the quality assessment provided by the corresponding Oxford Level of Evidence, whereby smaller circles indicate low-quality (i.e. Level 3b or 4, case series) and larger circles denote moderate-quality (i.e. Level 2a, systematic review with homogeneity of 2b or better studies and Level 2b, modeling studies) evidence. The color of the circle represents the reproduction number (R0) whereby blue indicates R0 <1.5, purple denotes R0 >1.5, turquoise represents studies with range of 1.5 > R0 < 1.5 (both), white shows R0 was not provided, and gray for systematic reviews that had a varied range of R0 values.